Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06807580 · ClinicalTrials.gov registry record · Phase 2
Progesterone in Gender Affirming Hormone Therapy Study
A Phase 2 study of Transgender Women, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06807580 is a Phase 2 study of Transgender Women that is actively recruiting participants, run by Emory University. The registered enrollment target is 40 participants, below the 68-participant average among 3 other Transgender Women trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06807580, a Phase 2 study of Transgender Women, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to study the effects of Oral Progesterone in Transgender Women. The primary goal is to study the effect of progesterone on psychological distress and secondarily on sleep quality, breast size, quality of life and gender congruence and cardiovascular risk.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Progesterone
Study Locations (1)
Georgia
- Emory Transgender Clinic - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-05-12 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06807580
The ClinicalTrials.gov registry entry for NCT06807580 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 68-participant average among 3 other Transgender Women trials with a reported enrollment target (41% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transgender Women appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06807580 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06807580 about?
NCT06807580 is a clinical study titled "Progesterone in Gender Affirming Hormone Therapy Study". This study aims to study the effects of Oral Progesterone in Transgender Women. The primary goal is to study the effect of progesterone on psychological distress and secondarily on sleep quality, breast size, quality of life and gender congruence and cardiovascular risk.
What is the current status of trial NCT06807580?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-05-12. Estimated completion is 2027-02.
What conditions does trial NCT06807580 study?
This clinical trial studies the following conditions: Transgender Women.
What interventions are being tested in trial NCT06807580?
The interventions under investigation include: Placebo (DRUG), Progesterone (DRUG).
Who is sponsoring clinical trial NCT06807580?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06807580 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transgender Women
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Economic Navigation and Strengthening to Research Unrestricted Services for Transgender Women (ENTRUST)
RECRUITING · NA
-
To Reach Unrestricted Services for Transgender Women
COMPLETED · NA
-
Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.